Home/ Stocks/ CELC

Celcuity Inc. Common Stock

CELC XNAS

$102.01 -4.74 (-4.44%) ▼ 15-min delayed

Open

$105.49

High

$105.83

Low

$100.01

Volume

606.2K

Market Cap

$4.94B

About Celcuity Inc. Common Stock

Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

Sector: SERVICES-MEDICAL LABORATORIES Employees: 87 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q3 2025	$0	$-43,804,000	$-0.92
Q2 2025	$0	$-45,268,000	$-1.04
Q1 2025	$0	$-36,997,000	$-0.86
FY 2024	$0	$-111,779,105	$-2.83

Earnings & Analyst Ratings

Next Earnings: Tue, May 12, 2026

Calendar →

Related Market News

No specific coverage for CELC yet. Check out our latest market news or earnings calendar.

Get CELC Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Celcuity Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.